Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Industry Insights Seminar Series - Past Events

Industry Insights Seminars in 2025

  • Dr Kay Penicud - Apollo Therapeutics - Collaborating with Apollo Therapeutics: bridging the gap from Academia to Pharma - first steps on the translation from bench to bedside
  • Dr Marta Cortes-Cros - Novartis - Targeting the WRN helicase in MSI cancers
  • Dr Murielle Veniant - Amgen - Maridebart Cafraglutide (Maritide) -an investigational drug for the treatment of obesity - from bench to clinic
  • Dr Oliver Harrison - Royal Society EIR in Oxford- CEO of Koa Health - Opportunities in healthcare AI at Oxford
  • Mohammed Ismael - Olink- Working alongside UK Biobank
  • Dr Robert Wilkinson - Immunocore - Progress Towards Targeted Immunotherapy for Cancer

Industry Insights Seminars in 2024

  • Kuldeep Singh, Mradul Kanugo - Softude,  Dr. Joseph Davids - Imperial College London- From Paperwork to Patients: AI in Healthcare
  • Dr Thomas Freeman - Johnson & Johnson Innovative Medicine - The impacts of omics data on translational science
  • Professor Nadeem Sarwar  - Novo Nordisk - Prevention is better than cure – realising a sustainable new paradigm to predict and pre-empt obesity and its consequences
  • Nicholas Zoulias - Azenta - Harnessing the power of multiomics from a single sample to explore tumor heterogeneity and advancing immuno-oncology
  • Dr Shea Hamilton - Somalogic - The transformative role of Somascan for protein biomarker discovery, validation and translation
  • Dr Sarantis Chlamydas – Olink - Precision proteomics broadens MultiOmics repertoire and enables biomarker discovery
  • Christel Iffland, Chris Birchall - OmniAb-Opening the Barn Door to Antibody Discovery with OmniAb
  • Jayne Wallace - Oxford Nanopore - Democratising sequencing: Latest from Oxford Nanopore Technologies
  • Luke Devey – Quell - Restoring the balance with Regulatory T Cell Therapies/ Opportunities and Challenges in Biotech, 2024

Industry Insights Seminars in 2023

  • Balaji Modhagala, Subhagata Chattopadhyay – SquareML - AI-ML in Healthcare: Predicting 30-day Post-discharge Unplanned Readmission Risks in the Elderly - a Use Case
  • Casper Wilstrup – Abzu - Augmenting Drug Discovery with AI
  • Quin Wills - Ochre Bio - Maintaining Human Livers Outside of the Body
  • Jo Howson - Novo Nordisk - Genetics and Drug Discovery
  • Jonathan Kwok – Infinitopes - UK positioning as a cancer vaccine superpower- hyperbole or reality? Infinitopes as a CRUK-led cancer vaccine spinout from the Oxford ecosystem
  • Lisa Caproni - Touchlight - The Making of DNA:  The role of enzymatic doggybone DNA in enabling future genetic medicines
  • Daniel Tomé, Mariana Fontes – Olink - Understanding human disease in the post-genomics era
  • Hussein - Al-Mossawi – AstraZeneca - Targeting type 1 IFN in immune-mediated inflammatory disease

Industry Insights Seminars in 2022

  • Iris-Valerie Stracke – Psious - Virtual reality and mental health
  • William Drewe, Martin Main - Medicines Discovery Catapult - Advancing UK Medicines Discovery through Innovative Partnerships
  • Jack Pearson - Natural Cycles - Natural Cycles: Revolutionising research in Women's Health
  • Jason Crain – IBM - Physical modelling and machine intelligence for accelerated discovery
  • Yatish Lad - Oxford BioMedica - Gene therapy – coming of age
  • Martin-Immanuel Bittner – Arctoris - Combining robotics and AI: the emergence of data-driven drug discovery
  • Anna Hakes – BridgeBio - Bridgebio Pharma: turning translational academic research into medicines for patients with genetic diseases

Industry Insights Seminars in 2021

  • Ramneek Gupta - Novo Nordisk Research Centre Oxford - Target Discovery Opportunities using Machine Learning on Longitudinal Patient Journeys
  • Anjan Thakurta – BMS- Translational Fellowships: Perspectives from a BMS mentor and 5 Oxford fellows 
  • David Price -Vertex - Humanising drugs
  • Katharina Duerr - OMass - Development of Novel Medicines using high resolution native mass spectrometry of intact protein assemblies
  • Dr Manuela Zonca – PsiOxus - Tumour re-engineering
  • Joanna Gould – VisusNano - Novel drug-delivery in ophthalmology
  • Jane Osbourn, Paul Kellam – BIA - Accelerating Covid-19 Antibody Discovery Through Industry-Academia Consortium
  • Joe Fitchett - Mologic     - Transforming the path for equitable access to rapid diagnostics for epidemics
  • Ilona Gutcher – Bayer - Targeting the Aryl Hydrocarbon Receptor (AHR) as a novel immunotherapy for the treatment of cancer
  • David Lowe – Evox - Exosome-Based Therapies for the Treatment of Rare Genetic Diseases
In this section